Twitter Logo Youtube Circle Icon LinkedIn Icon

Publishing firms

Legal Developments worldwide

Life in life sciences in March and April 2011

July 2011 - Intellectual Property. Legal Developments by Norrbom Vinding Law Firm, member of ius laboris.

More articles by this firm.

Danish companies in the life sciences sector formed strategic alliances, were granted product approvals and took other initiatives in March and April 2011. Norrbom Vinding provides you with an overview of events:

Bavarian Nordic A/S
The Danish vaccine producer Bavarian Nordic announced in mid-April 2011 that they had prevailed in an arbitration against a German research institute. The Germans had claimed that they were entitled to royalties on the use of Bavarian Nordic’s MVA-BN® technology because they had contributed to its development. The arbitral tribunal disagreed.
Bavarian Nordic further announced that the US Government has increased its contract for the supply of smallpox vaccines from about EUR 28m to about EUR 67m. The product in question is named IMVAMUNE®. The contract means that Bavarian Nordic will develop a freeze-dried version of the vaccine. Bavarian Nordic recently applied for a marketing authorisation for IMVAMUNE® in Canada.
H. Lundbeck A/S
There are enzymes which disturb nerve signals in the brain. But animal studies show that the compound Lu AF11167 may weaken certain types of these enzymes. The compound may therefore have great efficacy in the treatment of particularly Alzheimer’s, Huntington’s and schizophrenia. Lundbeck has now initiated phase I studies of the compound to determine its safety and pharmacokinetic profile.
Lundbeck’s Lexapro is marketed in Japan by Mochida Pharmaceutical Co. Ltd. Mochida announced in mid-April that the product had been granted a marketing authorisation by the Japanese medicines agency. But no date has yet been set for when the product will be placed on the market in Japan.
Novo Nordisk A/S
In March 2011, Novo Nordisk was granted a marketing authorisation for Victoza® in China. The authorisation covers the use of the product for the treatment of type 2 diabetes. Novo Nordisk expect to place the product on the Chinese market some time during the second half of 2011.
Novozymes A/S
The enzyme RONOZYME® is used in pig and poultry feed. If this enzyme is added, the animals will absorb nutrients from the feed more easily. Now the Danish enzyme producer Novozymes has obtained an authorisation from the EU authorities to use the enzyme product in fish feed as well. This is good news for salmon and trout farmers because it means that they can reduce their feed costs.
The above does not constitute legal advice and should not be relied upon as such

For more information please visit